Tygacil

Tygacil is a brand name of tigecycline, approved by the FDA in the following formulation(s):

TYGACIL (tigecycline - injectable; iv (infusion))

• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: June 15, 2005
  
  Strength(s): 50MG/VIAL ^[RLD]

Has a generic version of Tygacil been approved?

No. There is currently no therapeutically equivalent version of Tygacil available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tygacil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tigecycline compositions and methods of preparation
  Patent 7,879,828
  Issued: February 1, 2011
  Inventor(s): Fawzi; Mahdi B. & Zhu; Tianmin & Shah; Syed M.
  Assignee(s): Wyeth LLC
  The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
  
  Patent expiration dates:
  
  
  • February 5, 2029
    
    ✓ 
    Drug product
  
  



• 
  Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
  Patent RE40086
  Issued: February 19, 2008
  Inventor(s): Hlavka; Joseph J. & Sum; Phaik-Eng & Gluzman; Yakov & Lee; Ving J. & Ross; Adma A.
  Assignee(s): Wyeth Holdings Corporation
  The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.
  
  Patent expiration dates:
  
  
  • June 25, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  
  



• 
  7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
  Patent RE40183
  Issued: March 25, 2008
  Inventor(s): Hlavka; Joseph J. & Sum; Phaik-Eng & Gluzman; Yakov & Lee; Ving J. & Ross; Adma A.
  Assignee(s): Wyeth Holdings Corporation
  The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.
  
  Patent expiration dates:
  
  
  • April 9, 2016
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 20, 2012 - COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
  
  
  • March 20, 2012 - ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
  
  
  • March 20, 2012 - ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
  
  

See also...

• Tygacil Consumer Information (Drugs.com)
• Tygacil Consumer Information (Wolters Kluwer)
• Tygacil Consumer Information (Cerner Multum)
• Tygacil Advanced Consumer Information (Micromedex)
• Tygacil AHFS DI Monographs (ASHP)
• Tigecycline Consumer Information (Wolters Kluwer)
• Tigecycline Consumer Information (Cerner Multum)
• Tigecycline Intravenous Advanced Consumer Information (Micromedex)
• Tigecycline AHFS DI Monographs (ASHP)